Tag Archive | "terminations"

Teva, a top pharma company halts tests of cancer drug biosimilar

Tags: , , ,


Teva Pharmaceutical Industries, a top pharma establishments has suspended testing of its generic version of Rituxan, a $7-billion a year drug, at the third stage of clinical trials Read the full story

Merck ends Vernakalant pharma deals with Cardiome Pharma

Tags: , , , ,


Cardiome Pharma announced that big pharma Merck wishes to terminate its existing pharma deals and hence will return the global marketing and development rights for both the intravenous and oral formulations for vernakalant to Cardiome Read the full story

AstraZeneca calls off its pharma partnering with Palatin Technologies

Tags: , , ,


Palatin Technologies announced that its collaboration partner, AstraZeneca, has decided to discontinue their pharma partnering agreement for the development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity Read the full story

AstraZeneca terminate pharma deals with BTG owing to drug trial failure

Tags: , , ,


An experimental drug for severe sepsis from AstraZeneca and BTG failed to help patients in a crucial mid-stage clinical trial and its development will now be halted, terminating pharma deals between AstraZeneca and BTG Read the full story

Pfizer terminates bapineuzumab pharma partnering with Johnson & Johnson

Tags: , , , ,


Big pharma, Pfizer and Johnson & Johnson announced that their pharma partnering pact for phase 3 clinical development of bapineuzumab intravenous  in mild-to-moderate Alzheimer's disease is being discontinued.

Read the full story

Takeda terminates pharma licensing agreement for Galaxy Biotech

Tags: , , , ,


Galaxy Biotech, LLC, a biotechnology company focused on developing monoclonal antibodies for the treatment of cancer, announced that it has received notice from Takeda Pharmaceutical Company terminating its pharma licensing pact from Galaxy Biotech to develop and commercialize humanized L2G7 (also designated as HuL2G7 and TAK-701), an antibody that targets hepatocyte growth factor (HGF).

Read the full story

Top deal terminations of 2011

Tags: ,


During 2011 there were eleven partnering deal terminations where the value of the original deal was in excess of $500 million Read the full story

Disappointing trial results end TC-5214 collaboration

Tags: , ,


The deal was announced with fanfare in 2009 with a headline value of $1.24 billion, but was terminated recently as a result of disappointing phase III study results Read the full story

AstraZeneca and Targacept terminate collaborative R&D and licensing agreement for TC-5214

Tags: , , ,


AstraZeneca and Targacept announced top-line results from the remaining Phase 3 studies investigating efficacy, tolerability and safety of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder who did not respond adequately to initial antidepressant treatment.  Read the full story

Pfizer scraps insulin deal with Biocon

Tags: , , ,


Pfizer has scrapped a deal to sell insulin products made by Biocon Ltd., leaving India's biggest biotechnology company without a partner to sell the drugs in key markets such as the United States. Read the full story

cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif
cabannerad300x150new4gif
rauconbadgejpg
amsbanner300x150jpg